Bookmark

Add to MyYahoo RSS

DePuy Orthopaedics News

News on DePuy Orthopaedics (Ticker: JNJ) continually updated from thousands of sources around the net.

9 hrs ago | Wall Street Journal

J&J Seeks Buyer for Cordis Unit

Johnson & Johnson plans to seek a buyer for a business that makes medical devices including stents and catheters, said people familiar with the matter, the latest effort by the health care giant to pare its wide-ranging portfolio.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

13 hrs ago | TheStreet.com

Why Johnson & Johnson (JNJ) Stock Is Declining Today

The FDA announced that the recall was of the most serious Class 1 category as the device can cause serious injury or death.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

19 hrs ago | Reuters

FDA says Johnson & Johnson recalls some jaw implants

Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw following more than a dozen cases of injury.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Food and Drug Administration, Medical Equipment, Hospital Administration, St Peters Health Care Services

19 hrs ago | CBC News

Jaw implants recalled

Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw, following more than a dozen cases of injury.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

23 hrs ago | TheStreet.com

Frustrating Boston Scientific Is Not What the Investor Ordered

The shares peaked in January at $14.08 and have grossly underperformed its peers ever since.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Thu Aug 21, 2014

BioSpace

ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Signing Of Rights Agreement With

The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01 combination product that ViaCyte is developing for type 1 diabetes.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Forbes.com

Dow Movers: BA, JNJ

Our mission at Market News Video is to produce and distribute quality online videos about the stock markets and publicly traded companies.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Mon Aug 18, 2014

Forbes.com

Interesting April 2015 Stock Options for Johnson & Johnson

Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson .

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Wed Aug 13, 2014

Seeking Alpha

Why I Ignored My Own Advice And Bought Johnson & Johnson Sans Pullback

In my opinion, Johnson & Johnson is an attractive investment given its vibrant growth and 51 consecutive years of dividend increases.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Mon Aug 11, 2014

Forbes.com

One Put, One Call Option To Know About for Johnson & Johnson

Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Johnson & Johnson .

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Tue Aug 05, 2014

TheStreet.com

Johnson & Johnson Can Only Get Better When It Gets Cheaper

This is a company that has increased its dividend for 52 consecutive years, in this year by 6%.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Mon Aug 04, 2014

FindLaw

J&J Power Morcellators Pulled Amid Cancer Fears

Johnson & Johnson is pulling power morcellators used for performing hysterectomies , responding to concerns that the devices risk spreading cancer to healthy tissues.

Comment?

Related Topix: Food, J and J Snack Foods, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Medical Equipment, Hospital Administration, St Peters Health Care Services

Fri Aug 01, 2014

Forbes.com

The Best Blood Cancer Drug Launch Ever?

Last night, Pharmacyclics reported a quarterly loss of 26 cents per share, far higher than the 11 cents forecast by Wall Street analysts, as it paid $50 million to Johnson & Johnson to help cover the launch of its cancer drug Imbruvica, which J&J co-markets.

Comment?

Related Topix: Startups, Pharmacyclics, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Medical Equipment, Hospital Administration, St Peters Health Care Services

Law Firm Newswire

First Two DePuy Pinnacle Cases Trial-Ready by September 1, Notes Rottenstein Law Group LLP

Rockville Centre, NY August 1, 2014 - The Rottenstein Law Group LLP is currently representing plaintiffs with claims stemming from injuries allegedly caused by metal-on-metal DePuy Pinnacle hip replacement devices .

Comment?

Related Topix: Rockville Centre, NY, Medicine, Medical Equipment, Healthcare Industry

Thu Jul 31, 2014

Journal Watch

J&J Withdraws Power Morcellators

Johnson & Johnson is withdrawing its laparoscopic power morcellators from hospitals amid concerns that the devices may potentially spread undetected uterine sarcoma during fibroid removal and hysterectomy, the Wall Street Journal reports.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

TheStreet.com

Why Johnson & Johnson (JNJ) Stock Is Lower Today

The company plans to tell customers world-wide in a letter today to return the devices known as laparoscopic power morcellators, the Journal said, STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

National Public Radio

Senate Antitrust Panel Eyes Contact Lens Pricing Policies

Under "UPP," or universal pricing policies, manufacturers like Johnson & Johnson tell retailers they can't sell their contact lens below a certain price.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

Wed Jul 30, 2014

The Washington Post

J&J Pulls From Market Hysterectomy Device Tied to Cancer Spread

Johnson & Johnson is pulling from the global market a device used during hysterectomies and other uterine procedures after reports that it may spread and accelerate the growth of undetected cancer inside women.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, Acclarent, Medical Equipment, Hospital Administration, St Peters Health Care Services

The News Tribune

J&J withdraws fibroid treatment device from market

In April, J&J suspended sales of the devices, known as laparoscopic power morcellators, after the Food and Drug Administration discouraged doctors from using them.

Comment?

Related Topix: Food, J and J Snack Foods, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Medical Equipment, Hospital Administration, St Peters Health Care Services

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••